Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04255381
Other study ID # 1609018413
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2018
Est. completion date December 31, 2020

Study information

Verified date May 2022
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this clinical study is to determine the feasibility, safety, and preliminary effectiveness of the Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system in pediatric subjects with type 1 diabetes in an ambulatory semi-supervised environment over a short duration of 3 days and 2 nights, or up to 60 hours.


Description:

The artificial pancreas platform employed under study is centered about the following four key innovations: 1) A zone model predictive control strategy that is at the same time very safe with respect to hypoglycemia, and can simultaneously and independently be tuned with respect to its response to hyperglycemia; 2) Zone control with diurnal blood-glucose target zones; 3) Models of insulin-glucose physiology and insulin on board; 4) A system for alarming and notification of impending hypoglycemia and technical malfunctions: the Health Monitoring System. These features have been evaluated in several clinical trials in adults with unannounced meals and exercise. The proposed study will evaluate enhancements to our previous system tailored for the special needs of pediatric subjects: 1) A control strategy with responses to hyperglycemia and hypoglycemia spanning wide ranges, as is typical with children; 2) The use of time-dependent zones specific for pediatric subjects; 3) The development of models for young children, capturing the greater physiologic variability, and ensuring cautious insulin delivery; 4) remote alarming and notification systems that are useful to parents.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria: 1. Age 2- <18 years; for first cohort(s), subjects will be 12-17 years; additional age brackets will be 8-11 years and then <8 years 2. Type 1 diabetes for = 1 year duration - the diagnosis of type 1 diabetes will be based on the history of ketosis/ketoacidosis at diagnosis or laboratory evidence of islet-cell auto-immunity 3. A1c level = 10.0% 4. Use of insulin pump and carbohydrate counting for = 3 months 5. Average total daily insulin dose of at least 10 units/day 6. Current or past use of Continuous Glucose Monitoring (CGM) is desirable but NOT required 7. Normal renal function as measured within 6 months of enrollment 8. Normal thyroid function within 6 months of enrollment, or if previously diagnosed with hypothyroidism, documented within 3 months of enrollment 9. Parent/guardian agrees to stay at hotel with subject for duration of hotel phase and has cell phone that can send/receive text messages 10. Subject and participating parent/guardian speak and comprehend English Exclusion Criteria: 1. Episode of diabetic ketoacidosis (DKA) within 6 months of enrollment 2. Episode of severe hypoglycemia (seizure, loss of consciousness) within 6 months of enrollment 3. Use of medications (other than insulin) known to affect BG levels within 4 weeks of enrollment - examples include systemic glucocorticoids, metformin, pramlintide, liraglutide) 4. Current use of other medications, that in opinion of investigator, would interfere with safety or effectiveness of the study including acetaminophen 5. Medical disorder, that in opinion of investigator, would be contraindication for inclusion; hypothyroidism and celiac disease are NOT exclusion if under good control 6. Female subjects of childbearing potential unwilling to have pregnancy testing 7. Female subject currently pregnant or lactating 8. History of alcohol or drug abuse, documented eating disorder, or inpatient psychiatric treatment within 6 months of enrollment 9. Subject is currently participating in another research study involving an investigational drug or device

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)

Locations

Country Name City State
United States Yale University New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University Harvard University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hypoglycemia Safety: Number of Participants With Blood Glucose (BG)) Readings < 50 Milligrams/Deciliter (mg/dL)) Number of participants with more than one confirmed BG < 50 mg/dL 60 hours
Primary Hyperglycemia Safety: Number of Participants With More Than Two Blood Glucose (BG) Readings > 300 mg/dL Longer Than 2 Hour or Any BG 400 > Milligrams/Deciliter (mg/dL)) No more than two confirmed BG = 300 mg/dL longer than 2 hours, and no BG = 400 mg/dL, unless determined to be from an infusion site failure. 60 hours
Primary Blood Ketone Safety: Number of Participants With Blood Ketone Levels > 1.0 mmol/l for Longer Than 2 Hours or Any Ketone Level> 3.0 mmol/l Number of participants with blood ketone level > 1.0 mmol/l for longer than 2 hours, and no blood ketone level >3.0 mmol/L, unless determined to be from an infusion site. failure 60 hours
Primary Safety: Number of Participants Who Experienced an Adverse Event Adverse events include seizure, loss of consciousness, severe hypoglycemia, diabetic ketoacidosis 60 hours
Secondary Mean Meter and Sensor Glucose Levels Milligram/Deciliter (mg/dL) Mean meter and sensor glucose levels (mg/dL) 60 hours
Secondary Percent Sensor Glucose Time in Range (70-180 mg/dL) Percentage of time, over the whole evaluation period, during which the glucose level, as determined by the continuous glucose sensor, is between 70-180 mg/dL 60 hours
Secondary Percent Sensor Glucose Time Below Range (<70 mg/dL) Percentage of time, over the whole evaluation period, during which the glucose level, as determined by the continuous glucose sensor, is below 70 mg/dL 60 hours
Secondary Percent Sensor Glucose Time Above Range (>180 mg/dL) Percentage of time, over the whole evaluation period, during which the glucose level, as determined by the continuous glucose sensor, is greater than 180 mg/dL 60 hours
Secondary Percent Sensor Glucose Time in Hypoglycemia (<60 mg/dL) Percentage of time, over the whole evaluation period, during which the glucose level, as determined by the continuous glucose sensor, is below 60 mg/dL 60 hours
Secondary Percent Sensor Glucose Time in Hyperglycemia (>250 mg/dL) Percentage of time, over the whole evaluation period, during which the glucose level, as determined by the continuous glucose sensor, is greater than 250 mg/dL 60 hours
Secondary Percent Time AP System Active Percentage of time, over the whole evaluation period, during which the sensor and pump are determined to be wirelessly connected and communicating with each other, based on duration of alert and error messages indicated by the system 60 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05536232 - Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet N/A
Completed NCT04625595 - Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes Phase 1
Active, not recruiting NCT06177691 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
Completed NCT04002557 - Optimising Consultation Summaries to Promote Good Health
Completed NCT05876273 - Neural-net Artificial Pancreas (NAP) N/A
Withdrawn NCT03236558 - The Role of the Thymus in Type I Diabetes. N/A
Completed NCT03179280 - Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia N/A
Completed NCT06253351 - Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes
Completed NCT01357603 - Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM Phase 1
Completed NCT04233034 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes Phase 3
Not yet recruiting NCT06408207 - CGM Academy for Youth With Type 1 Diabetes N/A
Recruiting NCT06408558 - Safe Use of New Technologies in Diabetes in Flight N/A
Active, not recruiting NCT03782636 - Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) Phase 2
Completed NCT04520971 - Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes N/A
Recruiting NCT05766657 - Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases N/A
Completed NCT01838083 - Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus Phase 1